RU2337692C2 - Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3 - Google Patents

Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3 Download PDF

Info

Publication number
RU2337692C2
RU2337692C2 RU2004116472/15A RU2004116472A RU2337692C2 RU 2337692 C2 RU2337692 C2 RU 2337692C2 RU 2004116472/15 A RU2004116472/15 A RU 2004116472/15A RU 2004116472 A RU2004116472 A RU 2004116472A RU 2337692 C2 RU2337692 C2 RU 2337692C2
Authority
RU
Russia
Prior art keywords
treatment
formula
tyrosine kinase
receptor tyrosine
vii
Prior art date
Application number
RU2004116472/15A
Other languages
English (en)
Other versions
RU2337692C3 (ru
RU2004116472A (ru
Inventor
Дуглас ГРИФФИН Джеймс (US)
Дуглас ГРИФФИН Джеймс
Уилль м МАНЛИ Пол (CH)
Уилльям МАНЛИ Пол
Original Assignee
Новартис Аг
Дана-Фарбер Кэнсер Инститьют Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26991080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2337692(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг, Дана-Фарбер Кэнсер Инститьют Инк. filed Critical Новартис Аг
Publication of RU2004116472A publication Critical patent/RU2004116472A/ru
Application granted granted Critical
Publication of RU2337692C2 publication Critical patent/RU2337692C2/ru
Publication of RU2337692C3 publication Critical patent/RU2337692C3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

Изобретение относится к области фармакологии и медицины и касается применения N-[(9S,10R,11R,13R)-2,3,10,11,12,13-гексагидро-10-метокси-9-метил-1-оксо-9,13-эпокси-1Н,9Н-дииндоло[1,2,3-gh:3',2',1'-lm]пирроло[3,4-j][1,7]бензодиазонин-11-ил]-N-метилбензамида формулы (VII) или его соли для получения фармацевтической композиции, предназначенной для лечения заболеваний, связанных с неконтролируемой активностью рецепторной тирозинкиназы FLT3, фармацевтического препарата и изделия, содержащих соединение формулы (II). Изобретение обеспечивает высокую эффективность лечения. 3 н. и 3 з.п. ф-лы, 1 табл.

Description

Текст описания приведен в факсимильном виде.
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066

Claims (8)

1. Применение N-[(9S,10R,11R,13R)-2,3,10,11,12,13-гексагидро-10-метокси-9-метил-1-оксо-9,13-эпокси-1Н,9Н-дииндоло[1,2,3-gh:3',2',1'-lm]пирроло[3,4-j][1,7]бензодиазонин-11-ил]-N-метилбензамида формулы (VII)
Figure 00000067
или его соли для получения фармацевтической композиции, предназначенной для лечения заболеваний, связанных с неконтролируемой активностью рецепторной тирозинкиназы FLT3.
2. Применение по п.1 для лечения лейкозов и миелодиспластических синдромов.
3. Применение по п.1 для лечения острого миелолейкоза и миелодиспластических синдромов с высоким риском.
4. Фармацевтический препарат для лечения лейкозов, включающий N-[(9S,10R,11R,13R)-2,3,10,11,12,13-гексагидро-10-метокси-9-метил-1-оксо-9,13-эпокси-1Н,9Н-дииндоло[1,2,3-gh:3',2',1'-lm]пирроло[3,4-j][1,7]бензодиазонин-11-ил]-N-метилбензамид формулы (VII) в эффективном количестве.
5. Изделие, включающее упаковочный материал и N-[(9S,10R,11R,13R)-2,3,10,11,12,13-гексагидро-10-метокси-9-метил-1-оксо-9,13-эпокси-1Н,9Н-дииндоло[1,2,3-gh:3',2',1'-lm]пирроло[3,4-j][1,7]бензодиазонин-11-ил]-N-метилбензамид формулы (VII) по п.1 или его фармацевтически приемлемые соли, содержащийся в указанном упаковочном материале, причем указанный упаковочный материал включает этикетки-инструкции, в которых сообщается, что указанное соединение формулы (VII) или его фармацевтически приемлемую соль следует вводить млекопитающим, страдающим от заболеваний, связанных с неконтролируемой активностью рецепторной тирозинкиназы FLT3, в количестве от 220 до 230 мг по специальной схеме лечения для ингибирования развития заболевания, связанного с неконтролируемой активностью рецепторной тирозинкиназы FLT3.
6. Изделие по п.5, где соединение формулы VII вводят три раза в сутки в общей дозе от 220 до 230 мг и предпочтительно в дозе от 70 до 80 мг при каждом введении, для лечения лейкозов, прежде всего острого миелолейкоза и миелодиспластических синдромов с высоким риском.
Приоритет по пунктам:
30.10.2001 по пп.1-4;
29.10.2002 по пп.5 и 6.
RU2004116472A 2001-10-30 2002-10-29 Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3 RU2337692C3 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33903101P 2001-10-30 2001-10-30
US60/339,031 2001-10-30
US33818501P 2001-12-07 2001-12-07
US60/338,185 2001-12-07

Publications (3)

Publication Number Publication Date
RU2004116472A RU2004116472A (ru) 2005-05-10
RU2337692C2 true RU2337692C2 (ru) 2008-11-10
RU2337692C3 RU2337692C3 (ru) 2020-11-09

Family

ID=26991080

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004116472A RU2337692C3 (ru) 2001-10-30 2002-10-29 Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3

Country Status (26)

Country Link
US (3) US7973031B2 (ru)
EP (1) EP1441737B1 (ru)
JP (1) JP4959918B2 (ru)
KR (2) KR100926194B1 (ru)
CN (2) CN101703509A (ru)
AT (1) ATE335490T1 (ru)
AU (1) AU2006249245B2 (ru)
BR (1) BRPI0213739B8 (ru)
CA (1) CA2462657C (ru)
CY (1) CY1106199T1 (ru)
DE (1) DE60213842T2 (ru)
DK (1) DK1441737T3 (ru)
ES (1) ES2269793T3 (ru)
FR (1) FR18C1012I2 (ru)
HK (1) HK1068262A1 (ru)
HU (1) HU230798B1 (ru)
IL (2) IL161156A0 (ru)
MX (1) MXPA04004137A (ru)
NO (1) NO335685B1 (ru)
NZ (1) NZ532136A (ru)
PL (1) PL211461B1 (ru)
PT (1) PT1441737E (ru)
RU (1) RU2337692C3 (ru)
TW (1) TWI302836B (ru)
WO (1) WO2003037347A1 (ru)
ZA (1) ZA200402498B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2598378C2 (ru) * 2009-11-30 2016-09-27 Новартис Аг Кристаллические формы iii и iv n-бензоилстауроспорина

Families Citing this family (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
WO2005011598A2 (en) * 2003-07-31 2005-02-10 University Of South Florida Leukemia treatment method and composition
WO2005014004A1 (en) * 2003-08-08 2005-02-17 Novartis Ag Combinations comprising staurosporines
US20080221080A1 (en) * 2003-08-25 2008-09-11 James Douglas Griffin Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias
CA2545711A1 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
WO2005053704A1 (en) * 2003-12-01 2005-06-16 Novartis Ag Method for predicting drug responsiveness in myeloid neoplasms
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
CN101022799A (zh) * 2004-07-19 2007-08-22 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
US20090156602A1 (en) * 2004-11-24 2009-06-18 Nigel Graham Cooke Organic Compounds
GB0426821D0 (en) * 2004-12-07 2005-01-12 Novartis Ag Organic compounds
ME02461B (me) 2005-05-10 2017-02-20 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US20080207591A1 (en) * 2005-07-20 2008-08-28 Manley Paul W Organic Compounds
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
WO2007048088A2 (en) 2005-10-18 2007-04-26 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
GB0522932D0 (en) * 2005-11-10 2005-12-21 Univ Southampton PKC412 in treatment of atypical chronic myeloid leukemia
CA2629478C (en) 2005-11-14 2013-10-15 Universitat Zurich Staurosporine derivatives for use in alveolar rhabdomyosarcoma
UA98449C2 (en) 2005-12-13 2012-05-25 Инсайт Корпорейшин Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
KR101367645B1 (ko) 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물
US8859602B2 (en) 2006-04-20 2014-10-14 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
GB0612542D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Combinations comprising staurosporines
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
MY152948A (en) 2007-11-16 2014-12-15 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
JP5275371B2 (ja) 2008-03-11 2013-08-28 インサイト・コーポレイション Ｊａｋ阻害剤としてのアゼチジン誘導体およびシクロブタン誘導体
WO2009132202A2 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
MY171866A (en) 2008-07-08 2019-11-05 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
LT2432472T (lt) 2009-05-22 2020-02-10 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
JP5946768B2 (ja) 2009-10-09 2016-07-06 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ３−（４−（７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１Ｈ−ピラゾール−１−イル）−３−シクロペンチルプロパンニトリルのヒドロキシル、ケト及びグルクロニド誘導体
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US9109227B2 (en) 2010-01-05 2015-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
JP5734313B2 (ja) 2010-01-12 2015-06-17 アーべー・シオンス チアゾールおよびオキサゾールキナーゼ阻害剤
CA2790070C (en) 2010-02-18 2018-03-06 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
CN103002875B (zh) 2010-05-21 2016-05-04 因塞特控股公司 Jak抑制剂的局部用制剂
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
CN103732226B (zh) 2011-02-18 2016-01-06 诺瓦提斯药物公司 mTOR/JAK抑制剂组合疗法
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AU2013251749B2 (en) * 2012-04-24 2019-01-17 International Stem Cell Corporation Derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
ES2608628T3 (es) 2012-08-07 2017-04-12 Janssen Pharmaceutica Nv Procedimiento para la preparacion de derivados de ester heterociclicos
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
MX2015005428A (es) 2012-11-01 2015-07-21 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
MY191357A (en) 2012-11-15 2022-06-19 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
TW202214254A (zh) 2013-03-01 2022-04-16 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
UA120162C2 (uk) 2013-03-06 2019-10-25 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
TWI719401B (zh) 2013-05-17 2021-02-21 美商英塞特公司 作為jak抑制劑之聯吡唑衍生物
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
CN105555313A (zh) 2013-08-20 2016-05-04 因赛特公司 在c-反应蛋白水平较高的实体肿瘤患者中的存活益处
US10463658B2 (en) * 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EA201691745A1 (ru) 2014-02-28 2016-12-30 Инсайт Корпорейшн Ингибиторы jak1 для лечения миелодиспластических синдромов
CU24481B1 (es) 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
PL3129021T3 (pl) 2014-04-08 2021-05-31 Incyte Corporation Leczenie nowotworów złośliwych z komórek b za pomocą skojarzenia inhibitora jak i pi3k
WO2015168246A1 (en) 2014-04-30 2015-11-05 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
AU2015295288B2 (en) 2014-07-31 2019-10-31 Centre National De La Recherche Scientifique (Cnrs) FLT3 receptor antagonists
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TWI748941B (zh) 2015-02-27 2021-12-11 美商英塞特公司 Ｐｉ３ｋ抑制劑之鹽及製備方法
TN2017000375A1 (en) 2015-03-10 2019-01-16 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
SG11201803520PA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
MA43169B1 (fr) 2015-11-06 2022-05-31 Incyte Corp Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
EP3400221B1 (en) 2016-01-05 2020-08-26 Incyte Corporation Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors
CN106083830B (zh) * 2016-06-01 2019-07-12 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3359155A4 (en) 2016-11-02 2019-05-22 Arog Pharmaceuticals, Inc. CRENOLANIB FOR THE TREATMENT OF MUTATIONS ASSOCIATED WITH FLT3-MUTED PROLIFERATIVE DISEASES
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CA3062981A1 (en) 2017-05-17 2018-11-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Flt3 inhibitors for improving pain treatments by opioids
US11331313B2 (en) 2017-05-22 2022-05-17 Whitehead Institute For Biomedical Research KCC2 expression enhancing compounds and uses thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107417743B (zh) * 2017-06-15 2020-07-21 杭州科兴生物化工有限公司 星孢菌素醛基取代衍生物及其制备方法和应用
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11306079B2 (en) 2017-12-21 2022-04-19 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
KR20200129099A (ko) 2018-01-30 2020-11-17 인사이트 코포레이션 (1-(3-플루오로-2-(트리플루오로메틸)이소니코티닐)피페리딘-4-온)의 제조 방법
IL276725B2 (en) 2018-02-16 2024-09-01 Incyte Corp JAK1 pathway inhibitors for the treatment of cytokine-related disorders
IL303087B1 (en) 2018-02-27 2024-08-01 Incyte Corp Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors
SI3762368T1 (sl) 2018-03-08 2022-06-30 Incyte Corporation Aminopirazin diolne spojine kot zaviralci PI3K-y
JP7565798B2 (ja) 2018-03-30 2024-10-11 インサイト・コーポレイション 炎症性皮膚疾患のバイオマーカー
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
DK3788047T3 (da) 2018-05-04 2024-09-16 Incyte Corp Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
WO2019227007A1 (en) 2018-05-25 2019-11-28 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN113166153A (zh) 2018-07-05 2021-07-23 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
JP2021535182A (ja) 2018-09-05 2021-12-16 インサイト・コーポレイションIncyte Corporation ホスホイノシチド３−キナーゼ（ｐｉ３ｋ）阻害剤の結晶形態
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US20210403495A1 (en) 2018-11-01 2021-12-30 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EP3923949A1 (en) 2019-02-15 2021-12-22 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
TW202112377A (zh) 2019-06-10 2021-04-01 美商英塞特公司 藉由jak抑制劑局部治療白斑症
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022543062A (ja) 2019-08-01 2022-10-07 インサイト・コーポレイション Ｉｄｏ阻害剤の投与レジメン
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2021041360A1 (en) 2019-08-26 2021-03-04 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
US11839619B2 (en) 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
EP4135844A1 (en) 2020-04-16 2023-02-22 Incyte Corporation Fused tricyclic kras inhibitors
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
US11685731B2 (en) 2020-06-02 2023-06-27 Incyte Corporation Processes of preparing a JAK1 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
EP4213800A1 (en) 2020-09-16 2023-07-26 Incyte Corporation Topical treatment of vitiligo
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
EP4259131A1 (en) 2020-12-08 2023-10-18 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
TW202317565A (zh) 2021-07-07 2023-05-01 美商英塞特公司 作為kras抑制劑的三環化合物
JP2024529347A (ja) 2021-07-14 2024-08-06 インサイト・コーポレイション Ｋｒａｓの阻害剤としての三環式化合物
EP4396187A1 (en) 2021-08-31 2024-07-10 Incyte Corporation Naphthyridine compounds as inhibitors of kras
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
JP2024537824A (ja) 2021-10-01 2024-10-16 インサイト・コーポレイション ピラゾロキノリンｋｒａｓ阻害剤
IL312114A (en) 2021-10-14 2024-06-01 Incyte Corp Quinoline compounds as Kras inhibitors
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
TW202320792A (zh) 2021-11-22 2023-06-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
WO2023102184A1 (en) 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
AR128043A1 (es) 2021-12-22 2024-03-20 Incyte Corp Sales y formas sólidas de un inhibidor de fgfr y procesos para su preparación
TW202341982A (zh) 2021-12-24 2023-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｃｄｋ２抑制劑及其用途
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
AR128717A1 (es) 2022-03-07 2024-06-05 Incyte Corp Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2
US20230399331A1 (en) 2022-06-14 2023-12-14 Incyte Corporation Solid forms of jak inhibitor and process of preparing the same
CN114853784B (zh) * 2022-06-16 2023-09-05 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种十字孢碱类化合物及其制备方法与应用
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
US20240101557A1 (en) 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
TW202419088A (zh) 2022-08-05 2024-05-16 美商英塞特公司 使用ｊａｋ抑制劑之蕁麻疹治療

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JP2766360B2 (ja) 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
CA2015996C (en) 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
AU7035991A (en) * 1989-12-14 1991-07-18 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
US5658895A (en) * 1991-10-07 1997-08-19 Otsuka Pharmaceutical Factory, Inc. Anticancer enteral feeding composition
EP0540185A1 (en) 1991-10-10 1993-05-05 Schering Corporation 4'-(N-substituted-N-oxide)staurosporine derivatives
ES2136103T3 (es) 1992-06-22 1999-11-16 Kyowa Hakko Kogyo Kk Procedimiento para la preparacion de derivados de estaurosporina.
WO1994002486A1 (en) 1992-07-20 1994-02-03 Syntex (U.S.A.) Inc. Novel chemiluminescent compounds and methods of use
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
WO1995032976A1 (en) 1994-06-01 1995-12-07 Ciba-Geigy Ag Polycyclic lactam derivatives for sensitizing multidrug-resistant cells to antitumour agents
EP0711557A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733358A3 (de) 1995-03-21 1998-05-20 Novartis AG Intravenös applizierbare Nanosuspensionen
JPH09299092A (ja) * 1996-03-12 1997-11-25 Takeda Chem Ind Ltd 新規タンパク質およびそのｄｎａ
AU4205597A (en) * 1996-08-20 1998-03-06 Novartis Ag Methods for prevention of cellular proliferation and restenosis
EP0925061B1 (en) 1996-08-22 2005-12-28 Jagotec Ag Compositions comprising microparticles of water-insoluble substances and method for preparing same
CO4940430A1 (es) 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
JP2001523707A (ja) 1997-11-26 2001-11-27 イーライ・リリー・アンド・カンパニー 慢性骨髄性白血病および急性リンパ性白血病のための治療的処置
DE69940158D1 (de) 1998-08-20 2009-02-05 Chugai Pharmaceutical Co Ltd Verfahren zum screenen von potenziellen verbindungen für das auffinden von einem anti-tumor-arzneistoff
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2598378C2 (ru) * 2009-11-30 2016-09-27 Новартис Аг Кристаллические формы iii и iv n-бензоилстауроспорина

Also Published As

Publication number Publication date
HU230798B1 (hu) 2018-06-28
BRPI0213739B8 (pt) 2021-05-25
CA2462657A1 (en) 2003-05-08
HK1068262A1 (en) 2005-04-29
IL161156A0 (en) 2004-08-31
US20120252785A1 (en) 2012-10-04
ZA200402498B (en) 2005-07-27
US8445479B2 (en) 2013-05-21
ES2269793T3 (es) 2007-04-01
FR18C1012I2 (fr) 2021-06-11
DE60213842T2 (de) 2007-09-06
AU2006249245A1 (en) 2007-01-04
NZ532136A (en) 2006-08-31
FR18C1012I1 (fr) 2018-04-27
US8222244B2 (en) 2012-07-17
PL368322A1 (en) 2005-03-21
IL161156A (en) 2011-02-28
CN1582150B (zh) 2011-09-07
CA2462657C (en) 2011-04-26
RU2337692C3 (ru) 2020-11-09
JP2005507412A (ja) 2005-03-17
EP1441737B1 (en) 2006-08-09
BRPI0213739B1 (pt) 2020-06-09
RU2004116472A (ru) 2005-05-10
PT1441737E (pt) 2006-12-29
TWI302836B (en) 2008-11-11
PL211461B1 (pl) 2012-05-31
DK1441737T3 (da) 2006-11-13
US7973031B2 (en) 2011-07-05
NO335685B1 (no) 2015-01-19
WO2003037347A1 (en) 2003-05-08
KR100926194B1 (ko) 2009-11-09
US20110224194A1 (en) 2011-09-15
MXPA04004137A (es) 2005-01-25
KR20090087139A (ko) 2009-08-14
KR20050040842A (ko) 2005-05-03
HUP0401642A3 (en) 2008-05-28
CN1582150A (zh) 2005-02-16
EP1441737A1 (en) 2004-08-04
ATE335490T1 (de) 2006-09-15
AU2006249245B2 (en) 2009-11-05
TW200301127A (en) 2003-07-01
JP4959918B2 (ja) 2012-06-27
NO20042123L (no) 2004-07-13
HUP0401642A2 (hu) 2004-11-29
CY1106199T1 (el) 2011-06-08
DE60213842D1 (de) 2006-09-21
CN101703509A (zh) 2010-05-12
BR0213739A (pt) 2004-10-19
US20050020570A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
RU2337692C2 (ru) Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3
ITRM920155A1 (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
RU93057724A (ru) Фармацевтическая композиция, способ ее получения и способ лечения
HUP0004040A1 (hu) Antimikrobiális hatású pleuromutilinszármazékok, eljárás ezek előállítására, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
EP1435240A3 (en) Solid oral dosage form comprising a combination of methformin and glibenclamide
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
JP2005512995A5 (ru)
ES2039262T3 (es) Uso de acetil l-carnitina para la preparacion de un medicamento para el tratamiento terapeutico de neuropatias perifericas.
HUP0201877A2 (hu) Hal zselatint tartalmazó, gyorsan diszpergálódó dózis formák
ATE122668T1 (de) Diarylsubstituierte heterocyclische verbindung, ihre herstellung und arzneimittel und kosmetika daraus.
AP2003002763A0 (en) Controlled release formulations for oral administration
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
ES2634026T3 (es) Composiciones medicinales
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time
OA07029A (fr) Le chlorure de gallium, nouveau médicament anti-cancéreux.
AR030145A1 (es) Sal farmaceuticamente aceptable de morfolinobenzamida o solvato de la misma, formulacion farmaceutica que la contiene, su uso para la fabricacion de un medicamento y proceso para la preparacion de dicha sal o solvato
TR200103473T2 (tr) Kristalli azabisiklo (2.2.2) oktan-3-amin sitratin polimorfları ve farmasötik kompozisyonları.
JP2005525391A5 (ru)
EP1545511B1 (en) Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder
GB9420748D0 (en) 1,5 benzodiazepine derivatives
RU2002129356A (ru) Комбинация лекарственных средств для лечения головной боли, содержащая нестероидное противовоспалительное лекарственное средство
AR124542A1 (es) Métodos de tratamiento
KR890014116A (ko) 고혈압치료 혼합물

Legal Events

Date Code Title Description
ND4A Extension of patent duration

Effective date: 20201109